BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38426083)

  • 21. The pretreatment albumin to globulin ratio as a significant predictor in patients with diffuse large B cell lymphoma.
    Yue W; Liu B; Gao L; He M; Wang J; Zhang W; Chen L; Hu X; Xu L; Yang J
    Clin Chim Acta; 2018 Oct; 485():316-322. PubMed ID: 30006285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.
    Chen H; Zhong Q; Zhou Y; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Zhou L; Shi Y
    BMC Cancer; 2022 May; 22(1):583. PubMed ID: 35624433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Characteristics and Outcomes of AIDS-Related Burkitt Lymphoma in China: A Retrospective Single-Center Study.
    Liu R; Zhao H; Xiao G; Tao Y; Tang X; Feng L; Liao B; Liu B; Guan J; Li L; Chen Z; He H; You H
    Technol Cancer Res Treat; 2024; 23():15330338231214236. PubMed ID: 38179657
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expression of CD30 in Patients with Diffuse Large B-Cell Lymphoma and Clinical Significance].
    Qu Y; Lu XZ; Wang RX; Hei XF; Li J; Xiao BT; Jia ZX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):450-457. PubMed ID: 38660851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Red blood cell distribution width as a simple negative prognostic factor in patients with diffuse large B-cell lymphoma: a retrospective study.
    Periša V; Zibar L; Sinčić-Petričević J; Knezović A; Periša I; Barbić J
    Croat Med J; 2015 Aug; 56(4):334-43. PubMed ID: 26321026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma.
    Miao Y; Zhou XH; Guo JJ; Sun Q; Shi K; Wu JZ; Zhu HY; Wang L; Fan L; Xu W; Li JY
    Cancer Med; 2019 Jun; 8(6):2751-2758. PubMed ID: 30980510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of pretreatment red blood cell distribution width in primary diffuse large B-cell lymphoma of the central nervous system for 3P medical approaches in multiple cohorts.
    Li D; Li S; Xia Z; Cao J; Zhang J; Chen B; Zhang X; Zhu W; Fang J; Liu Q; Hua W
    EPMA J; 2022 Sep; 13(3):499-517. PubMed ID: 36061828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Role of Red Cell Distribution Width (RDW) in Patients with Diffuse Large B-cell Lymphoma.
    Kamandi N; Soleimanian A; Allahyari A; Kamandi M
    Asian Pac J Cancer Prev; 2023 Aug; 24(8):2667-2672. PubMed ID: 37642052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
    Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
    Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of red blood cell distribution width and D-Dimer in diffuse large B-cell lymphoma: Systematic review and meta-analysis.
    Rahchamani M; Sedghi M; Hakimi A; Nejatianfar M; Javaheri T; Tavakoli R; Ahmadi R; Makarem M; Azmi-Naei N; Zahmatkesh Sangani S; Kamandi N; Soleimanian A; Shavaleh R; Foogerdi M; Rahmani K
    Cancer Rep (Hoboken); 2024 Jan; 7(1):e1936. PubMed ID: 37997648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the Predictive Power of the Hemoglobin/Red Cell Distribution Width Ratio in Cancer: A Systematic Review and Future Directions.
    Coradduzza D; Medici S; Chessa C; Zinellu A; Madonia M; Angius A; Carru C; De Miglio MR
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138227
    [No Abstract]   [Full Text] [Related]  

  • 33. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
    Troppan KT; Schlick K; Deutsch A; Melchardt T; Egle A; Stojakovic T; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Pichler M
    Br J Cancer; 2014 Jul; 111(1):55-60. PubMed ID: 24874478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic immune inflammation index, ratio of lymphocytes to monocytes, lactate dehydrogenase and prognosis of diffuse large B-cell lymphoma patients.
    Wu XB; Hou SL; Liu H
    World J Clin Cases; 2021 Nov; 9(32):9825-9834. PubMed ID: 34877321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
    Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study.
    Huang X; Wang Y; Huang Z; Chen X; Lin Q; Huang H; Fan L
    BMC Cancer; 2024 Jan; 24(1):62. PubMed ID: 38212711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.
    Nicolaides C; Fountzilas G; Zoumbos N; Skarlos D; Kosmidis P; Pectasides D; Karabelis A; Giannakakis T; Symeonidis A; Papadopoulos A; Antoniou F; Pavlidis N
    Oncology; 1998; 55(5):405-15. PubMed ID: 9732217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
    Nakayama S; Matsuda M; Adachi T; Sueda S; Ohashi Y; Awaji S; Hashimoto S; Matsumura I
    Platelets; 2019; 30(5):637-645. PubMed ID: 30047815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
    Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
    Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.